Skip to main content
Log in

Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

Mice were pretreated with reserpine plusα-methyl-p-tyrosine (10 mg/ kg plus 200 mg/kg). One hour later they were administered the selective dopamine D-2 agonist bromocriptine or vehicle. Three hours after the bromocriptine, mice were challenged with the selective D-1 agonist SKF 38393, and locomotor activity was measured each 5 min for three hours. Neither bromocriptine nor SKF 38393 produced significant stimulation. The combination, however, produced a dose-dependent and coordinated increase in activity. If the bromocriptine was given only one hour before the SKF 38393 challenge (i.e., three hours after the reserpine plusα-methyl-p-tyrosine), no interaction was seen. In naive mice, when SKF 38393 and bromocriptine were administered together, the locomotor response to bromocriptine was quantitatively and qualitatively altered. The initial depressant response to bromocriptine was shortened, producing a more rapid onset of the stimulant response. In one experiment, the maximal activity induced by bromocriptine was increased by SKF 38393. The ability of SKF 38393 to alter the locomotor stimulant effect of bromocriptine in naive mice was blocked by their pretreatment with the selective D-1 antagonist, SCH 23390. The data indicate that the locomotor stimulant effects of bromocriptine are modulated by D1 receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Ahlenius S (1974) Effects of L-DOPA on conditioned avoidance responding after behavioural suppression byα-methyltyrosine or reserpine in mice. Neuropharmacology 13: 729–739

    PubMed  Google Scholar 

  • Bailey RC, Jackson DM (1978) A pharmacological study of changes in central nervous system receptor responsiveness after long-term dexamphetamine and apomorphine administration. Psychopharmacology 56: 317–326

    PubMed  Google Scholar 

  • Bannon MJ, Grace AA, Bunney BS, Roth RH (1980) Evidence for an irreversible interaction of bromocriptine with central dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol 312: 37–41

    PubMed  Google Scholar 

  • Breese GR, Muller RA (1985) SCH 23390 antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons. Eur J Pharmacol 113: 109–114

    PubMed  Google Scholar 

  • Brodde O-E, Freistühler J, Meyer F-J (1981) Stereospecific antagonism by d-butaclamol of dopamine-induced relaxation of the isolated rabbit mesenteric artery. J Cardiovasc Pharmacol 3: 828–837

    PubMed  Google Scholar 

  • Christensen AV, Arnt J, Hyttel L, Larsen JJ, Sverdsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 334: 1529–1540

    Google Scholar 

  • Costall B, Eniojukan JF, Naylor RJ (1983) The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour. Eur J Pharmacol 96: 201–210

    PubMed  Google Scholar 

  • Di Chiara G, Porceddu ML, Vargiu L, Stefanini E, Gessa GL (1977) Evidence for selective and long-lasting stimulation of “regulatory” dopaminereceptors by bromocriptine (CB-154). Naunyn Schmiedebergs Arch Pharmacol 300: 239–245

    PubMed  Google Scholar 

  • Dray A, Oakley NR (1976) Bromocriptine and dopamine-receptor stimulation. J Pharm Pharmacol 28: 586–588

    PubMed  Google Scholar 

  • Flückiger E (1978) Effects of bromocriptine on the hypothalamo-pituitary axis. Acta Endocrinologica 88 [suppl]: 111–117

    Google Scholar 

  • Fuller RW, Perry KW (1982) Effect of haloperidol pre-and post-treatment on the ability of pergolide and bromocriptine to antagonize the gammabutyrolactone-induced increase in brain dopamine in rats. Biochem Pharmacol 31: 2199–2200

    PubMed  Google Scholar 

  • Fuxe K, Fredholm BB, Agnati LF, ögren S-O, Everitt BJ, Jonsson G, Gustafsson J-å (1978a) Interaction between ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders. Pharmacology 16 [suppl]: 99–134

    PubMed  Google Scholar 

  • Fuxe K, Fredholm BB, ögren S-O, Agnati LF, Hökfelt T, Gustafsson J-å (1978b) Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioural analysis. Fed Proc 37: 2181–2191

    PubMed  Google Scholar 

  • Fuxe K, Fredholm BB, ögren S-O, Agnati LF, Hökfelt T, Gustafsson J-å (1978c) Pharmacological and biochemical evidence for the dopanine agonist effect of bromocriptine. Acta Endocrinologica 88 [suppl]: 27–56

    Google Scholar 

  • Gmelin GW (1978) Microelectrophoretic studies with 2-bromo-α-ergocriptine on dopaminergic neurons in the feline caudate nucleus. Life Sci 23: 485–487

    PubMed  Google Scholar 

  • Goldstein M, Lieberman A, Meller E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. Trends Pharmacol Sci 6: 436–437

    Google Scholar 

  • Gundlach AL, Krstich M, Beart PM (1983) Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates. Brain Res 278: 155–163

    PubMed  Google Scholar 

  • Horowski R (1978) Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride, and d-LSD as compared with apomorphine. Eur J Pharmacol 51: 157–166

    PubMed  Google Scholar 

  • Hruska RE, Silbergeld EK (1981) Inhibition of neurotransmitter receptor binding by ergot derivatives. J Neurosci Res 6: 1–11

    PubMed  Google Scholar 

  • Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226: 462–468

    PubMed  Google Scholar 

  • Jackson DM, Hashizume M (1986) Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 receptors are stimulated with SKF 38393. Psychopharmacology 90: 147–149

    PubMed  Google Scholar 

  • Jackson DM, Jenkins OF (1985) Hypothesis: Bromocriptine lacks intrinsic dopamine receptor stimulating properties. J Neural Transm 62: 219–230

    PubMed  Google Scholar 

  • Jenkins OF, Jackson DM (1985) Bromocriptine potentiates the behavioural effects of directly-and indirectly-acting dopamine receptor agonists in mice. Naunyn Schmiedebergs Arch Pharmacol 331: 7–11

    PubMed  Google Scholar 

  • Jenkins OF, Jackson DM (1987) Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats. Neuropharmacology (in press)

  • Johnson AM, Loew DM, Vigouret J-M (1976) Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br J Pharmacol 56: 59–68

    PubMed  Google Scholar 

  • Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96

    PubMed  Google Scholar 

  • Lew JY, Hata F, Ohashi T, Goldstein M (1977) The interactions of bromocriptine and lergotrile with dopamine andα-adrenergic receptors. J Neural Transm 41: 109–121

    PubMed  Google Scholar 

  • Mailman RB, Schulz DW, Lewis MH, Staples L, Rollema H, De Haven DL (1984) SCH 23390: a selective D-1 dopamine antagonist with potent D-2 behavioural actions. Eur J Pharmacol 101: 159–160

    PubMed  Google Scholar 

  • Martin GE, Williams M, Haubrich DR (1982) A pharmacological comparison of 6, 7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine (3-PPP) with selected dopamine agonists. J Pharmacol Exp Ther 223: 298–304

    PubMed  Google Scholar 

  • Molloy AG, Waddington JL (1984) Dopaminergic behaviour stereospecifically promoted by the D-1 antagonist SCH 23390. Psychopharmacol 82: 409–410

    Google Scholar 

  • Molloy AG, Waddington JL (1985) Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK & F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide. Eur J Pharmacol 108: 305–308

    PubMed  Google Scholar 

  • Ogawa N, Yamawaki Y, Kuroda H, Ofuji T (1981) Effects of bromocriptine on receptor binding of methionine-enkephalin. Neurosci Lett 23: 215–218

    PubMed  Google Scholar 

  • Reavill C, Jenner P, Marsden CD (1980) Metabolite involvement in bromocriptine-induced circling behaviour in rodents. J Pharm Pharmacol 32: 278–284

    PubMed  Google Scholar 

  • Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50: 419–430

    PubMed  Google Scholar 

  • Sibley DR, Creese I (1983) Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Mol Pharmacol 23: 585–593

    PubMed  Google Scholar 

  • Silbergeld EK, Adler H, Kennedy S, Calne DB (1977) The roles of presynaptic function and hepatic drug metabolism in the hypothermic actions of two novel dopaminergic agonists. J Pharmacol 29: 632–635

    Google Scholar 

  • Strömbom U (1975) On the functional role of pre- and postsynaptic catecholamine receptors in brain. Acta Physiol Scand [suppl] 431: 1–43

    Google Scholar 

  • Walters JR, Baring MD, Lakoski JM (1979) Effects of ergolines on dopaminergic and serotonergic single unit activity. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon Press, Oxford, pp 207–221

    Google Scholar 

  • White FJ, Wang RY (1984) Pharmacological characterization of dopamine autoreceptor in the rat ventral tegmental area: microiontophoretic studies. J Pharmacol Exp Ther 231: 275–280

    PubMed  Google Scholar 

  • Winer BJ (1971) Statistical principles in experimental design. McGraw-Hill, Tokyo

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackson, D.M., Hashizume, M. Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors. J. Neural Transmission 69, 131–145 (1987). https://doi.org/10.1007/BF01244104

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01244104

Key words

Navigation